SOLV

— Fundamental Stock Analysis and Report Card

Healthcare : Medical - Care Facilities

Located in Maplewood, MN, US. Solventum Corporation, established in 2023 and headquartered in Saint Paul, Minnesota, operates as a healthcare entity dedicated to pioneering, producing, and commercializing diverse solutions that address critical needs for both customers and patients. The company's business activities are organized into four principal segments. The Medsurg division furnishes various products and services, including sophisticated wound care items, intravenous (I.V.) site management tools, sterilization assurance systems, temperature regulation devices, surgical instruments, stethoscopes, and medical electrodes. Its Dental Solutions segment provides a comprehensive range of dental and orthodontic offerings, such as brackets, clear aligners, restorative filling materials, and bonding agents. The Health Information Systems division concentrates on advanced software platforms, covering functionalities like computer-assisted physician documentation, direct billing and coding automation, classification frameworks, voice recognition capabilities, and data visualization tools. Finally, the Purification and Filtration segment supplies an array of purification and filtration technologies, including various filters, purifiers, cartridges, and specialized membranes.

Growth

Revenue, earnings and profitability.

Strong revenue growth and earnings can attract investors, driving the stock price up. Profitability indicates the company's efficiency and sustainability, which impacts investor confidence. Poor performance in these areas can lead to a decrease in stock price.

Revenue History

Earnings History

Margins

Gross Margin TTM
53.67%
EBITDA Margin TTM
33.33%
Net Margin TTM
17.33%
Earnings Per Share TTM
8.22
Statements

Income & Cash Flow analysis.

An income statement shows what a company earned and spent over a period — revenue at the top, costs and expenses in between, and net income at the bottom. A cash flow statement tracks the actual cash moving in and out, across operations, investing, and financing. Read together, they show whether reported earnings are backed by real cash.

Solventum Corporation
Select Period:
Q1 2026
Total ($)
Q1 2026
Margin (%)
Revenue
2.0b
-63.0m
-3.0%
Gross Income
1.1b
-17.0m
-1.5%
55%
+0.8pp
+1.6%
EBITDA
213.0m
-58.0m
-21.4%
11%
-2.5pp
-18.9%
Operating Income
81.0m
-71.0m
-46.7%
4%
-3.3pp
-45.0%
Net Income
13.0m
-124.0m
-90.5%
1%
-6.0pp
-90.2%
Earnings Per Share
0.07
-0.7
-91.1%
Operating Cash Flow
-189.0m
-218.0m
-751.7%
-9%
-10.8pp
-772.2%
Free Cash Flow
-273.0m
-193.0m
-241.2%
-14%
-9.7pp
-252.0%
Research & Development
189.0m
-4.0m
-2.1%
9%
+0.1pp
+1.0%